fda semaglutide shortage resolved feb 21 2025 compounded deadline As of February 21, 2025, the updated its drug list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and FDA Declares Wegovy and Ozempic

In most cases, mild skin reactions subside on their own without any intervention

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

An anticholinergic burden score of three or higher is associated with increased cognitive impairment and mortality

The reason people may have quinine pills around their house is that some people take them for nocturnal leg cramps

Sources: Cleveland Clinic: GLP-1 Agonists Wegovy.com Ozempic.com Goodwin Law: A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Ozempic FDA Approval History FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight Study identifies benefits, risks linked to popular weight-loss drugs Patients Are Left With Few Options as GLP-1 Copycats Disappear Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review HeadWise Podcast Transcript: Episode 195: GLP-1: Can It Help Headache and Migraine

That combination means Im going to give you a straight answer